Список проголосовавших за комментарий "А что значит без новостей. Вот в апреле получили одобрение в FDA на противоопухолевый препарат<br/> <blockquote>In April, the FDA approved <strong>Incyte</strong>’s selective FGFR inhibitor, <strong>Pemazyre</strong> (pemigatinib) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. This is the first of the three pipeline candidates lined up to receive approval in 2020.</blockquote><br/> Или вы именно про последние дни?"